Clinical trials: Intraperitoneal Chemotherapy, Bevacizumab, Ovarian Cancer
Intraperitoneal Chemotherapy, Bevacizumab, Ovarian Cancer
Intraperitoneal Chemotherapy Versus Triweekly Chemotherapy
The combination of paclitaxel and carboplatin is the standard first-line chemotherapy for ovarian cancer as recommended by the NCCN Guidelines for Epithelial Ovarian Cancer, and is conventionally given via intravenous route every…
- Trial name
- NCT05410938
- Testing
- Chemotherapy
- Where
- Taiwan
- Volunteers
- 59 people
- Sponsor
- Far Eastern Memorial Hospital
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
This randomized phase III trial studies bevacizumab and intravenous (given into a vein) chemotherapy to see how well they work compared with bevacizumab and intraperitoneal (given into the abdominal cavity) chemotherapy in…
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma
- Trial name
- NCT00951496
- Testing
- Bevacizumab, Carboplatin, Cisplatin
- Where
- 503 sites in United States
- Volunteers
- 1,560 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer With Malignant Ascites
Clinical Study in Treatment of Malignant Ascites of Ovarian Cancer With Intraperitoneal Injection Bevacizumab Combined With Intraperitoneal Hyperthermic Perfusion Chemotherapy
To study the efficacy and safety of intraperitoneal injection bevacizumab combined with intraperitoneal hyperthermic perfusion chemotherapy in treatment of malignant ascites of ovarian cancer.
- Trial name
- NCT01838538
- Testing
- Bevacizumab, TC:paclitaxel + carboplatin
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Chinese PLA General Hospital
Peritoneal Adhesion
Intraperitoneal Chemotherapy Alone or in Combination With Bevacizumab for Ovarian Cancer With Peritoneal Adhesion
Background: Malignant peritoneal adhesion is a common complication and prognostic factor of ovarian cancer and other primary abdominal tumors.
- Trial name
- NCT03095001
- Testing
- Bevacizumab, Carboplatin, paclitaxel
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Chinese PLA General Hospital
Ovarian Cancer, Fallopian Tube Cancer
Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer
Phase I study to evaluate intraperitoneal carboplatin along with weekly intravenous paclitaxel and bevacizumab in order to establish a tolerable dose and define the toxicity of this regimen in previously untreated patients with…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, No Prior Chemotherapy
- Trial name
- NCT01220154
- Testing
- Paclitaxel, Carboplatin, Bevacizumab
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- David O'Malley
Advanced Ovarian Carcinoma, Primary Peritoneal Carcinoma
Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer
The purpose of this study is to evaluate the tolerability of intraperitoneal cisplatin with intravenous paclitaxel and Avastin as defined by the proportion of patients able to complete 6 cycles of treatment.
- Conditions
- Advanced Ovarian Carcinoma, Primary Peritoneal Carcinoma, Ovarian Carcinosarcoma
- Trial name
- NCT00511992
- Testing
- Avastin, Paclitaxel, Cisplatin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Oklahoma